Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels. This clinical trial is looking at hormone changes in women with stage IIIB or stage IV non-small cell lung cancer receiving erlotinib.
Patients undergo a dermatology evaluation and complete the Polycystic Ovarian Syndrome (PCOS) research study questionnaire once. Blood samples are collected after an overnight fast. Samples are analyzed for circulating levels of total and bioavailable testosterone, dehydroepiandrosterone sulfate, and sex hormone binding globulin. Serum luteinizing hormone, follicle stimulating hormone, fasting glucose, and insulin levels are also assessed.
Study Type
OBSERVATIONAL
Enrollment
10
Northwestern University, Northwestern Medical Faculty Foundation
Chicago, Illinois, United States
Presence of hyperandrogenemia
We will determine if hyperandrogenemia is present in women with nonsmall cell lung cancer who are taking erlotinib.
Time frame: One approximate 30 minute visit
Dermatologic manifestations
We will describe the dermatologic manifestations of erlotinib in women
Time frame: One approximate 30 minute visit
Changes in body habitus and patterns of hair loss
We will describe changes in body habitus and patterns of hair loss from women on erlotinib.
Time frame: One approximate 30 minute visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.